The prognosis of pediatric AIDS in Serbia

Current HIV Research

Volumn 7, Issue 3, 2009, Pages 287-292

  Jevtović, Djordje ^a   Salemović, Dubravka ^a   Ranin, Jovan ^a   Brmbolić, Branko ^a   Djurković Djakovoć, Olgica ^a  

^a UNIVERSITY OF BELGRADE   (Serbia)

Author keywords

HAART; Pediatric HIV AUDS; Prognosis

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; DIDANOSINE; LAMIVUDINE; LOPINAVIR; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANEMIA; CD4 LYMPHOCYTE COUNT; CHILD; DRUG TREATMENT FAILURE; ESOPHAGUS CANDIDIASIS; FEMALE; FOLLOW UP; GASTROINTESTINAL SYMPTOM; GRAM NEGATIVE SEPSIS; GRANULOMATOSIS; HEPATITIS B; HEPATITIS C; HERPES ZOSTER; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; HYPERSENSITIVITY; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNOREACTIVITY; LEUKOENCEPHALOPATHY; LIPODYSTROPHY; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MONOTHERAPY; PATIENT COMPLIANCE; PNEUMOCYSTIS PNEUMONIA; PRESCHOOL CHILD; PROGNOSIS; RASH; REVIEW; SCHOOL CHILD; SERBIA; SURVIVAL; TREATMENT DURATION; TREATMENT OUTCOME; VIREMIA; VIRUS TRANSMISSION; WASTING SYNDROME; ARTICLE; COHORT ANALYSIS; HIV ASSOCIATED LIPODYSTROPHY; INFANT; RETROSPECTIVE STUDY;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; FEMALE; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; INFANT; MALE; PROGNOSIS; RETROSPECTIVE STUDIES; SERBIA; TREATMENT OUTCOME; VIREMIA; YOUNG ADULT;

EID: 67649099433     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016209788347912     Document Type: Review

References (22)

1. Jacobson MA, French MAH. Altered natural history of AIDS-related opportunistic infections in the era of potent combination anti-retroviral therapy. AIDS 1998; 12 (suppl A): S157-S163.
2. Gea-Banacloche JC, Lane CH. Immune reconstitution in HIV infection. AIDS 1999; 13 (suppl A): S25-S38.
3. Carcelain G, Li T, Autran B. Immune reconstitution under highly active antiretroviral therapy (HAART). AIDS Rev 1999; 1: 51-6.
4. Gazzard BG, on behalf of the BHIVA Treatment Guidelines Writing Group. BHIVA guidelines for the treatment of HIV-1- infected adults with antiretroviral therapy. 2008; (Pre- press version). Available from: www.bhiva.org
5. Hammer SM, Eron JJ, Reiss P, et al. Antiretroviral therapy in adult HIV infections. Recommendations of International AIDS Society - USA Panel. JAMA 2008; 300: 555-70.
6. Jevtović Dj, Salemović D, Ranin J, Pešić I, Žerjav S, Djurković-Djaković O. Long-term survival of HIV-infected patients treated with highly active antiretroviral therapy in Serbia and Montenegro. HIV Med 2007; 8: 75-9.
7. Oleska JM. Treating children with HIV infection: what we can do, we should do? Clin Infect Dis 2007; 44: 605-6.
8. Puthanakit T, Aurpibul L, Oberdorfer P, et al. Hospitalization and mortality among HIV-infected children after receiving highly active antiretroviral therapy. Clin Infect Dis 2007; 44: 599-604.
9. Violari A, Cotton MF, Gibb DM, et al. Early antiretroviral therapy and mortality among HIV-infected infants. N Engl J Med 2008; 359: 2233-44.
10. De Baets AJ, Ramet J, Msellati P, Lepage P. The unique features of pediatric HIV-I in sub-Saharan Africa. Curr HIV Res 2008; 6: 351-62.
11. CDC. 1994 revised classification system for HIV infection and expanded surveillance case definition for human immunodeficiency virus infection in children less than 13 years of age. 1994 MMWR Morb Mortal Wkly 1994; 43 (RR-12): 1-10
12. Sande MA, Eliopoulos GE, Moellering RC, Gilbert DN, Eds. The Sanford Guide to HIV/AIDS Therapy 2008. 16th edition. Sperryville: Antimicrobial Therapy Inc 2007.
13. Pakker NG, Kroon EDMB, Roos MTL, et al. Immune restoration does not invariably occur following long-term HIV-1 suppression during antiretroviral therapy. AIDS 1999; 13: 203-12.
14. Jevtović Dj, Salemović D, Ranin J, Pešić I, Žerjav S, Djurković-Djaković O. The dissociation between virological and immunological responses to HAART. Biomed Pharmacother 2005; 59: 446-51.
15. Puthanakit T, Oberdorfer P, Akarathum N, Sirisanthana T, Sirisanthana V. Immune reconstitution syndrome after highly active antiretroviral therapy in human immunodeficiency virus-infected Thai children. Pediatr Infect Dis J 2006; 25: 53-8.
16. Durant J, Clevenbergh P, Halfon P, et al. Drug-resistance genotyping in HIV-1 therapy: the VIRADEPT randomised controlled trial. Lancet 1999; 353: 2195-9.
17. Faye A, Le Chenadec J, Dollfus C, et al. (for the French Perinatal Study Group). Early versus deferred antiretroviral multidrug therapy in infants infected with HIV type 1. Clin Infect Dis 2004; 39: 1692-8.
18. Viani RM, Araneta MRG, Devile JG, Spector SA. Decrease in hospitalization and mortality rates among children with perinatally acquired HIV type 1 infection receiving highly active antiretroviral therapy. Clin Infect Dis 2004; 39: 725-31.
19. Luzuriaga K, McManus M, Mofenson L. Britto P, Graham B, Sullivan JL, for the PACTG 356 investigators. A trial of three antiretroviral regimens in HIV-1 infected children. N Engl J Med 2004; 350: 2471-80.
20. Sutcliffe CG, van Dijk JH, Bolton C, Persaud D, Moss WJ. Effectiveness of antiretroviral therapy among HIV-infected children in sub-Saharan Africa. Lancet Infect Dis 2008; 8: 477-89.
21. Jevtović Dj, Salemović D, Ranin J, Pesić I, Žerjav S, Djurković-Djaković O. The incidence and risks for immune restoration disease in HAART-treated HIV patients treated with highly active antiretroviral therapy. HIV Med 2005; 6: 140-3.
22. Aurpibul L, Puthankit T, Lee B, Mangklabruks A, Sirisanthana T, Sirisanthana V. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007; 12: 1247-54.